Feasibility and Significance of Preclinical Diagnosis in Hypertrophic Cardiomyopathy
Authors:
- Efstathios D. PagoureliasEPEfstathios D. Pagourelias
- Stavros HadjimiltiadesSHStavros Hadjimiltiades
- Soultana MeditskouSMSoultana Meditskou
- Haralampos KarvounisHKHaralampos Karvounis
- William J. McKennaWMWilliam J. McKenna
- 1 November 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Cardiology in Review
- Vol. 23 (6) , 297-302
Abstract
Preclinical diagnosis in hypertrophic cardiomyopathy (HCM) refers to the detection of functional or histopathological abnormalities in subjects who carry any HCM-causing gene mutation, before or even without the development of left ventricular hypertrophy [genotype(+)/phenotype(-)subjects]. The concept that HCM pathology may exist in the absence of left ventricular hypertrophy is quite old but the ability to recognize the presence of early myocardial changes is quite new. Lessons from animal models have shown that in experimental human HCM, myocardial cell mechanical dysfunction precedes histopathological changes, such as myocyte disarray, fibrosis, and hypertrophy. Several clinical reports have demonstrated that the majority of HCM genotype(+)/phenotype(-) subjects display myocardial functional or histopathological changes, such as reduced tissue Doppler imaging-derived systolic and diastolic velocities, abnormal electrocardiogram, cardiac magnetic resonance-visualized myocardial crypts, mitral leaflet elongation, and evidence of a fibrotic state, such as increased type I procollagen synthesis, cardiac magnetic resonance-increased myocardial extracellular volume, and late gadolinium myocardial enhancement. All these signs have been proposed as preclinical markers of HCM. At present the separation of such a group of subjects in the early phase of their disease provides the opportunity to test new therapies to prevent the development of fibrosis, hypertrophy, and dysfunction.Keywords
This publication has 46 references indexed in Scilit:
- Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencingJournal of Medical Genetics, 2013
- Hypertrophic cardiomyopathyThe Lancet, 2013
- Genetics of Hypertrophic Cardiomyopathy After 20 YearsJACC, 2012
- Diagnostic, Prognostic, and Therapeutic Implications of Genetic Testing for Hypertrophic CardiomyopathyJACC, 2009
- Mutations in the Gene for Cardiac Myosin-Binding Protein C and Late-Onset Familial Hypertrophic CardiomyopathyNew England Journal of Medicine, 1998
- A Mouse Model of Familial Hypertrophic CardiomyopathyScience, 1996
- Hypertrophic cardiomyopathy — pathology and pathogenesisHistopathology, 1995
- A molecular basis for familial hypertrophic cardiomyopathy: A β cardiac myosin heavy chain gene missense mutationCell, 1990
- Hypertrophic cardiomyopathy without hypertrophy: two families with myocardial disarray in the absence of increased myocardial mass.Heart, 1990
- Development and Progression of Left Ventricular Hypertrophy in Children with Hypertrophic CardiomyopathyNew England Journal of Medicine, 1986